Conjugated Linoleic Triacylglycerols Exhibit Superior Lymphatic Absorption Than Free Conjugate Linoleic Acids and Have Antiobesity Properties

Hyunjoon Woo, Min Yu Chung, Juyeon Kim, Daecheol Kong, Jinyoung Min, Hee Don Choi, In Wook Choi, In-Hwan Kim, Sang K. Noh, Byung Hee Kim

Research output: Contribution to journalArticle

Abstract

This study aimed to compare lymphatic absorption of conjugated linoleic acids (CLAs) in the triacylglycerol (TAG) or free fatty acid (FFA) form and to examine the antiobesity effects of different doses of CLAs in the TAG form in animals. Conjugated linoleic TAGs (containing 70.3 wt% CLAs; CLA-TAG) were prepared through lipase-catalyzed esterification of glycerol with commercial CLA mixtures (CLA-FFA). Lymphatic absorption of CLA-TAG and CLA-FFA was compared in a rat model of lymphatic cannulation. Greater amounts of cis-9,trans-11 and trans-10,cis-12 CLAs were detected in the collected lymph from a lipid emulsion containing CLA-TAG. This result suggests that CLA-TAG has greater capacity for lymphatic absorption than does CLA-FFA. The antiobesity efficacy of CLA-TAG at different doses was examined in mice with diet-induced obesity. A high-fat diet (HFD) for 12 weeks caused a significant increase in body weight and epididymal and retroperitoneal fat weights, which were significantly decreased by 2% dietary supplementation (w/w) with CLA-TAG. CLA-TAG at 2% significantly attenuated the HFD-induced upregulation of serum TAG, but led to hepatomegaly and exacerbated HFD-induced hypercholesterolemia. CLA-TAG at 1% significantly attenuated upregulation of retroperitoneal fat weight and significantly increased liver weight, which was decreased by the HFD. Nonetheless, the liver weight in group "HFD +1% CLA-TAG" was not significantly different from that of normal diet controls. CLA-TAG at 1% significantly reduced serum TAG levels and did not exacerbate HFD-induced hypercholesterolemia. Thus, 1% dietary supplementation with CLA-TAG reduces retroperitoneal fat weight without apparent hepatomegaly, a known side-effect of CLAs in mouse models of obesity.

Original languageEnglish
Pages (from-to)486-494
Number of pages9
JournalJournal of Medicinal Food
Volume19
Issue number5
DOIs
Publication statusPublished - 2016 May 1

Fingerprint

Linoleic Acids
Conjugated Linoleic Acids
Triglycerides
High Fat Diet
Nonesterified Fatty Acids
Intra-Abdominal Fat
Weights and Measures
Hepatomegaly
Dietary Supplements
Hypercholesterolemia
Up-Regulation
Obesity
Diet

Keywords

  • Antiobesity
  • Conjugated linoleic triacylglycerol
  • High-fat diet
  • Lymphatic absorption

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Cite this

Conjugated Linoleic Triacylglycerols Exhibit Superior Lymphatic Absorption Than Free Conjugate Linoleic Acids and Have Antiobesity Properties. / Woo, Hyunjoon; Chung, Min Yu; Kim, Juyeon; Kong, Daecheol; Min, Jinyoung; Choi, Hee Don; Choi, In Wook; Kim, In-Hwan; Noh, Sang K.; Kim, Byung Hee.

In: Journal of Medicinal Food, Vol. 19, No. 5, 01.05.2016, p. 486-494.

Research output: Contribution to journalArticle

Woo, Hyunjoon ; Chung, Min Yu ; Kim, Juyeon ; Kong, Daecheol ; Min, Jinyoung ; Choi, Hee Don ; Choi, In Wook ; Kim, In-Hwan ; Noh, Sang K. ; Kim, Byung Hee. / Conjugated Linoleic Triacylglycerols Exhibit Superior Lymphatic Absorption Than Free Conjugate Linoleic Acids and Have Antiobesity Properties. In: Journal of Medicinal Food. 2016 ; Vol. 19, No. 5. pp. 486-494.
@article{f67d13ff1afa4b90b2218894f1d70900,
title = "Conjugated Linoleic Triacylglycerols Exhibit Superior Lymphatic Absorption Than Free Conjugate Linoleic Acids and Have Antiobesity Properties",
abstract = "This study aimed to compare lymphatic absorption of conjugated linoleic acids (CLAs) in the triacylglycerol (TAG) or free fatty acid (FFA) form and to examine the antiobesity effects of different doses of CLAs in the TAG form in animals. Conjugated linoleic TAGs (containing 70.3 wt{\%} CLAs; CLA-TAG) were prepared through lipase-catalyzed esterification of glycerol with commercial CLA mixtures (CLA-FFA). Lymphatic absorption of CLA-TAG and CLA-FFA was compared in a rat model of lymphatic cannulation. Greater amounts of cis-9,trans-11 and trans-10,cis-12 CLAs were detected in the collected lymph from a lipid emulsion containing CLA-TAG. This result suggests that CLA-TAG has greater capacity for lymphatic absorption than does CLA-FFA. The antiobesity efficacy of CLA-TAG at different doses was examined in mice with diet-induced obesity. A high-fat diet (HFD) for 12 weeks caused a significant increase in body weight and epididymal and retroperitoneal fat weights, which were significantly decreased by 2{\%} dietary supplementation (w/w) with CLA-TAG. CLA-TAG at 2{\%} significantly attenuated the HFD-induced upregulation of serum TAG, but led to hepatomegaly and exacerbated HFD-induced hypercholesterolemia. CLA-TAG at 1{\%} significantly attenuated upregulation of retroperitoneal fat weight and significantly increased liver weight, which was decreased by the HFD. Nonetheless, the liver weight in group {"}HFD +1{\%} CLA-TAG{"} was not significantly different from that of normal diet controls. CLA-TAG at 1{\%} significantly reduced serum TAG levels and did not exacerbate HFD-induced hypercholesterolemia. Thus, 1{\%} dietary supplementation with CLA-TAG reduces retroperitoneal fat weight without apparent hepatomegaly, a known side-effect of CLAs in mouse models of obesity.",
keywords = "Antiobesity, Conjugated linoleic triacylglycerol, High-fat diet, Lymphatic absorption",
author = "Hyunjoon Woo and Chung, {Min Yu} and Juyeon Kim and Daecheol Kong and Jinyoung Min and Choi, {Hee Don} and Choi, {In Wook} and In-Hwan Kim and Noh, {Sang K.} and Kim, {Byung Hee}",
year = "2016",
month = "5",
day = "1",
doi = "10.1089/jmf.2015.3627",
language = "English",
volume = "19",
pages = "486--494",
journal = "Journal of Medicinal Food",
issn = "1096-620X",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Conjugated Linoleic Triacylglycerols Exhibit Superior Lymphatic Absorption Than Free Conjugate Linoleic Acids and Have Antiobesity Properties

AU - Woo, Hyunjoon

AU - Chung, Min Yu

AU - Kim, Juyeon

AU - Kong, Daecheol

AU - Min, Jinyoung

AU - Choi, Hee Don

AU - Choi, In Wook

AU - Kim, In-Hwan

AU - Noh, Sang K.

AU - Kim, Byung Hee

PY - 2016/5/1

Y1 - 2016/5/1

N2 - This study aimed to compare lymphatic absorption of conjugated linoleic acids (CLAs) in the triacylglycerol (TAG) or free fatty acid (FFA) form and to examine the antiobesity effects of different doses of CLAs in the TAG form in animals. Conjugated linoleic TAGs (containing 70.3 wt% CLAs; CLA-TAG) were prepared through lipase-catalyzed esterification of glycerol with commercial CLA mixtures (CLA-FFA). Lymphatic absorption of CLA-TAG and CLA-FFA was compared in a rat model of lymphatic cannulation. Greater amounts of cis-9,trans-11 and trans-10,cis-12 CLAs were detected in the collected lymph from a lipid emulsion containing CLA-TAG. This result suggests that CLA-TAG has greater capacity for lymphatic absorption than does CLA-FFA. The antiobesity efficacy of CLA-TAG at different doses was examined in mice with diet-induced obesity. A high-fat diet (HFD) for 12 weeks caused a significant increase in body weight and epididymal and retroperitoneal fat weights, which were significantly decreased by 2% dietary supplementation (w/w) with CLA-TAG. CLA-TAG at 2% significantly attenuated the HFD-induced upregulation of serum TAG, but led to hepatomegaly and exacerbated HFD-induced hypercholesterolemia. CLA-TAG at 1% significantly attenuated upregulation of retroperitoneal fat weight and significantly increased liver weight, which was decreased by the HFD. Nonetheless, the liver weight in group "HFD +1% CLA-TAG" was not significantly different from that of normal diet controls. CLA-TAG at 1% significantly reduced serum TAG levels and did not exacerbate HFD-induced hypercholesterolemia. Thus, 1% dietary supplementation with CLA-TAG reduces retroperitoneal fat weight without apparent hepatomegaly, a known side-effect of CLAs in mouse models of obesity.

AB - This study aimed to compare lymphatic absorption of conjugated linoleic acids (CLAs) in the triacylglycerol (TAG) or free fatty acid (FFA) form and to examine the antiobesity effects of different doses of CLAs in the TAG form in animals. Conjugated linoleic TAGs (containing 70.3 wt% CLAs; CLA-TAG) were prepared through lipase-catalyzed esterification of glycerol with commercial CLA mixtures (CLA-FFA). Lymphatic absorption of CLA-TAG and CLA-FFA was compared in a rat model of lymphatic cannulation. Greater amounts of cis-9,trans-11 and trans-10,cis-12 CLAs were detected in the collected lymph from a lipid emulsion containing CLA-TAG. This result suggests that CLA-TAG has greater capacity for lymphatic absorption than does CLA-FFA. The antiobesity efficacy of CLA-TAG at different doses was examined in mice with diet-induced obesity. A high-fat diet (HFD) for 12 weeks caused a significant increase in body weight and epididymal and retroperitoneal fat weights, which were significantly decreased by 2% dietary supplementation (w/w) with CLA-TAG. CLA-TAG at 2% significantly attenuated the HFD-induced upregulation of serum TAG, but led to hepatomegaly and exacerbated HFD-induced hypercholesterolemia. CLA-TAG at 1% significantly attenuated upregulation of retroperitoneal fat weight and significantly increased liver weight, which was decreased by the HFD. Nonetheless, the liver weight in group "HFD +1% CLA-TAG" was not significantly different from that of normal diet controls. CLA-TAG at 1% significantly reduced serum TAG levels and did not exacerbate HFD-induced hypercholesterolemia. Thus, 1% dietary supplementation with CLA-TAG reduces retroperitoneal fat weight without apparent hepatomegaly, a known side-effect of CLAs in mouse models of obesity.

KW - Antiobesity

KW - Conjugated linoleic triacylglycerol

KW - High-fat diet

KW - Lymphatic absorption

UR - http://www.scopus.com/inward/record.url?scp=84969170521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969170521&partnerID=8YFLogxK

U2 - 10.1089/jmf.2015.3627

DO - 10.1089/jmf.2015.3627

M3 - Article

C2 - 27081749

AN - SCOPUS:84969170521

VL - 19

SP - 486

EP - 494

JO - Journal of Medicinal Food

JF - Journal of Medicinal Food

SN - 1096-620X

IS - 5

ER -